EXFY vs. DH, FSLY, EVER, WEAV, SCWX, PUBM, SMWB, VNET, TUYA, and DSP
Should you be buying Expensify stock or one of its competitors? The main competitors of Expensify include Definitive Healthcare (DH), Fastly (FSLY), EverQuote (EVER), Weave Communications (WEAV), SecureWorks (SCWX), PubMatic (PUBM), Similarweb (SMWB), VNET Group (VNET), Tuya (TUYA), and Viant Technology (DSP). These companies are all part of the "computer software" industry.
Expensify (NASDAQ:EXFY) and Definitive Healthcare (NASDAQ:DH) are both small-cap business services companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings.
Expensify has higher earnings, but lower revenue than Definitive Healthcare. Expensify is trading at a lower price-to-earnings ratio than Definitive Healthcare, indicating that it is currently the more affordable of the two stocks.
Expensify has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Comparatively, Definitive Healthcare has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.
In the previous week, Expensify had 2 more articles in the media than Definitive Healthcare. MarketBeat recorded 4 mentions for Expensify and 2 mentions for Definitive Healthcare. Definitive Healthcare's average media sentiment score of 0.79 beat Expensify's score of 0.43 indicating that Definitive Healthcare is being referred to more favorably in the news media.
68.4% of Expensify shares are owned by institutional investors. Comparatively, 98.7% of Definitive Healthcare shares are owned by institutional investors. 17.3% of Expensify shares are owned by insiders. Comparatively, 14.8% of Definitive Healthcare shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Expensify currently has a consensus target price of $2.63, suggesting a potential upside of 17.19%. Definitive Healthcare has a consensus target price of $5.64, suggesting a potential upside of 31.23%. Given Definitive Healthcare's higher probable upside, analysts plainly believe Definitive Healthcare is more favorable than Expensify.
Expensify has a net margin of -22.41% compared to Definitive Healthcare's net margin of -156.65%. Definitive Healthcare's return on equity of 0.98% beat Expensify's return on equity.
Definitive Healthcare received 6 more outperform votes than Expensify when rated by MarketBeat users. However, 30.36% of users gave Expensify an outperform vote while only 28.40% of users gave Definitive Healthcare an outperform vote.
Summary
Definitive Healthcare beats Expensify on 9 of the 17 factors compared between the two stocks.
Get Expensify News Delivered to You Automatically
Sign up to receive the latest news and ratings for EXFY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EXFY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Expensify Competitors List
Related Companies and Tools
